8-K: Veradigm Reaffirms 2023 Estimates and Provides Initial 2024 Financial Guidance Amid Delisting Challenges

Veradigm reaffirmed its 2023 financial estimates and provided initial 2024 guidance, projecting revenue between $620 million and $635 million and adjusted EBITDA between $104 million and $113 million, while navigating delisting from Nasdaq.

Summary

• Veradigm has reaffirmed its previously provided estimated, unaudited ranges for fiscal year 2023 for GAAP Revenue, Adjusted EBITDA, and Non-GAAP diluted earnings per share.
• The company has also introduced initial financial guidance for fiscal year 2024, projecting revenue between $620 million and $635 million.
• Adjusted EBITDA for 2024 is expected to be between $104 million and $113 million.
• Veradigm anticipates a net cash position of approximately $140 million following the acquisition of ScienceIO.
• The company is planning a year of investment across all lines of business in 2024, focusing on enhancing the Provider portfolio, expanding offerings to Payers, and developing new data offerings for Life Sciences with the integration of ScienceIO.
• Veradigm expects to see accelerated growth and margin expansion in the years following 2024.
• The company's core business is described as fundamentally sound and profitable, with ample internal liquidity.
• Veradigm is working to complete protracted audits spanning multiple years, including 2023.
• The company's common stock was delisted from Nasdaq effective February 29, 2024, and they are working towards relisting.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the delisting from Nasdaq, ongoing audit issues, and the temporary increase in operating expenses. While the company is projecting growth and has a solid core business, the challenges it faces are significant.

Positives

• The company's core business is fundamentally sound and profitable.
• Veradigm has ample internally available liquidity.
• The company is positioned for growth in the Payer and Life Sciences sectors.
• The acquisition of ScienceIO is expected to enhance Veradigm's data intelligence capabilities.
• Veradigm has a large network of over 400,000 providers and 200 million patient records.
• The company anticipates accelerated growth and margin expansion in the years following 2024.

Negatives

• Veradigm's common stock was delisted from Nasdaq effective February 29, 2024.
• The company is undergoing protracted audits spanning multiple years, including 2023.
• There is a temporary operating expense increase in 2024 impacting margins by -2%.
• The company is facing challenges related to the ongoing Audit Committee Investigation.
• There is a risk of further delays in financial reporting and the ability to hold an annual meeting of stockholders.

Risks

• The company faces risks associated with the integration of ScienceIO.
• There are risks related to the ongoing Audit Committee Investigation, including potential identification of additional errors and material weaknesses.
• The company is subject to a putative securities class action lawsuit.
• The delisting from Nasdaq poses risks, including the potential for convertible note holders to put the notes to the company or convert them into stock.
• There is a risk of further material delays in the company's financial reporting.
• The company is subject to a dynamic regulatory environment.

Future Outlook

Veradigm anticipates a year of investment in 2024 across all business lines, with the expectation of accelerated growth and margin expansion in the years following 2024. The company projects potential revenue growth to accelerate to 10%+ CAGR with gross margin expansion as higher margin Payer and AI data intelligence gains traction.

Management Comments

• Lee Westerfield, Interim CFO, stated that the core business remains fundamentally sound and profitable, backstopped by ample internally available liquidity.
• Dr. Yin Ho, Interim CEO, mentioned that Veradigm plans to build the first responsible, scaled language model products following the acquisition of ScienceIO.
• Dr. Yin Ho also stated that Veradigm will offer differentiated products in its Provider, Payer and Life Sciences businesses to support customers and ultimately result in higher quality and lower cost care for patients.

Industry Context

Veradigm's announcement comes at a time when the healthcare industry is increasingly focused on data-driven solutions and the use of AI. The company's focus on integrating ScienceIO and developing language model products aligns with this trend. The company is positioning itself as a leader in healthcare data intelligence.

Comparison to Industry Standards

• Veradigm's revenue guidance of $620M-$635M for 2024 is a modest growth of 1-3% from the midpoint of the 2023 estimated ranges, which is below the growth rates of some of its peers in the healthcare technology sector, such as Veeva Systems which has seen growth rates in the 15-20% range.
• The adjusted EBITDA margin of 17% at the midpoint of the 2024 guidance is impacted by a temporary opex bolus of $12M, which is a significant factor. Companies like Cerner (now Oracle Health) have historically maintained higher EBITDA margins, although they are also larger and more established.
• The company's focus on AI and real-world data is in line with industry trends, but the success of these initiatives will depend on the company's ability to execute and integrate ScienceIO effectively. Companies like Flatiron Health (acquired by Roche) have demonstrated the potential of real-world data in healthcare.
• The delisting from Nasdaq is a significant negative event, and the company's efforts to relist will be closely watched. Other companies that have faced similar challenges have often struggled to regain investor confidence.

Legal Proceedings

• The company is subject to a putative securities class action lawsuit related to the Audit Committee Investigation.

Stakeholder Impact

• Shareholders are negatively impacted by the delisting from Nasdaq and the ongoing audit issues.
• Employees may be affected by the company's restructuring and cost-cutting measures.
• Customers may experience some disruption as the company integrates ScienceIO and restructures its operations.
• Creditors may be concerned about the company's financial stability and ability to repay its debts.

Next Steps

• Veradigm will continue to work towards relisting on a national securities exchange.
• The company will focus on integrating ScienceIO and developing new data offerings.
• Veradigm will continue to work on completing its financial audits and restating its financial statements.
• The company will continue to engage with investors and stakeholders.

Key Dates

Keywords

Veradigm, Healthcare Data, Financial Guidance, Adjusted EBITDA, ScienceIO, Delisting, Audit Committee Investigation, Revenue, Net Cash, Healthcare Technology, AI, Real-World Data, EHR, Payers, Life Sciences